Skip to main content
main-content
Erschienen in: Supportive Care in Cancer 12/2015

01.12.2015 | Original Article

Quality-of-life outcomes in patients with gynecologic cancer referred to integrative oncology treatment during chemotherapy

verfasst von: Eran Ben-Arye, Noah Samuels, Elad Schiff, Orit Gressel Raz, Ilanit Shalom Sharabi, Ofer Lavie

Erschienen in: Supportive Care in Cancer | Ausgabe 12/2015

Einloggen, um Zugang zu erhalten

Abstract

Objective

Integrative oncology incorporates complementary medicine (CM) therapies in patients with cancer. We explored the impact of an integrative oncology therapeutic regimen on quality-of-life (QOL) outcomes in women with gynecological cancer undergoing chemotherapy.

Patients and methods

A prospective preference study examined patients referred by oncology health care practitioners (HCPs) to an integrative physician (IP) consultation and CM treatments. QOL and chemotherapy-related toxicities were evaluated using the Edmonton Symptom Assessment Scale (ESAS) and Measure Yourself Concerns and Wellbeing (MYCAW) questionnaire, at baseline and at a 6–12-week follow-up assessment. Adherence to the integrative care (AIC) program was defined as ≥4 CM treatments, with ≤30 days between each session.

Results

Of 128 patients referred by their HCP, 102 underwent IP consultation and subsequent CM treatments. The main concerns expressed by patients were fatigue (79.8 %), gastrointestinal symptoms (64.6 %), pain and neuropathy (54.5 %), and emotional distress (45.5 %). Patients in both AIC (n = 68) and non-AIC (n = 28) groups shared similar demographic, treatment, and cancer-related characteristics. ESAS fatigue scores improved by a mean of 1.97 points in the AIC group on a scale of 0–10 and worsened by a mean of 0.27 points in the non-AIC group (p = 0.033). In the AIC group, MYCAW scores improved significantly (p < 0.0001) for each of the leading concerns as well as for well-being, a finding which was not apparent in the non-AIC group.

Conclusions

An IP-guided CM treatment regimen provided to patients with gynecological cancer during chemotherapy may reduce cancer-related fatigue and improve other QOL outcomes.
Literatur
1.
Zurück zum Zitat Deng GE, Frenkel M, Cohen L, Cassileth BR, Abrams DI, Capodice J, Society for Integrative Oncology et al (2009) Evidence-based clinical practice guidelines for integrative oncology: complementary therapies and botanicals. J Soc Integr Oncol 7(3):85–120 PubMed Deng GE, Frenkel M, Cohen L, Cassileth BR, Abrams DI, Capodice J, Society for Integrative Oncology et al (2009) Evidence-based clinical practice guidelines for integrative oncology: complementary therapies and botanicals. J Soc Integr Oncol 7(3):85–120 PubMed
2.
Zurück zum Zitat Frenkel M, Cohen L, Peterson N, Palmer JL, Swint K, Bruera E (2010) Integrative medicine consultation service in a comprehensive cancer center: findings and outcomes. Integr Cancer Ther 9(3):276–283 CrossRefPubMed Frenkel M, Cohen L, Peterson N, Palmer JL, Swint K, Bruera E (2010) Integrative medicine consultation service in a comprehensive cancer center: findings and outcomes. Integr Cancer Ther 9(3):276–283 CrossRefPubMed
3.
Zurück zum Zitat Deng G (2008) Integrative Cancer Care in a US Academic Cancer Centre: the Memorial Sloan-Kettering Experience. Curr Oncol Suppl 15(2):s108.es68–s108.es71 Deng G (2008) Integrative Cancer Care in a US Academic Cancer Centre: the Memorial Sloan-Kettering Experience. Curr Oncol Suppl 15(2):s108.es68–s108.es71
4.
Zurück zum Zitat Helpman L, Ferguson SE, Mackean M, Rana A, Le L, Atkinson MA et al (2011) Complementary and alternative medicine use among women receiving chemotherapy for ovarian cancer in 2 patient populations. Int J Gynecol Cancer 21(3):587–593 CrossRefPubMed Helpman L, Ferguson SE, Mackean M, Rana A, Le L, Atkinson MA et al (2011) Complementary and alternative medicine use among women receiving chemotherapy for ovarian cancer in 2 patient populations. Int J Gynecol Cancer 21(3):587–593 CrossRefPubMed
5.
Zurück zum Zitat Nazik E, Nazik H, Api M, Kale A, Aksu M (2012) Complementary and alternative medicine use by gynecologic oncology patients in Turkey. Asian Pac J Cancer Prev 13(1):21–25 CrossRefPubMed Nazik E, Nazik H, Api M, Kale A, Aksu M (2012) Complementary and alternative medicine use by gynecologic oncology patients in Turkey. Asian Pac J Cancer Prev 13(1):21–25 CrossRefPubMed
6.
Zurück zum Zitat Rhode JM, Patel DA, Sen A, Schimp VL, Johnston CM, Liu JR (2008) Perception and use of complementary and alternative medicine among gynecologic oncology care providers. Int J Gynaecol Obstet 103(2):111–115 CrossRefPubMed Rhode JM, Patel DA, Sen A, Schimp VL, Johnston CM, Liu JR (2008) Perception and use of complementary and alternative medicine among gynecologic oncology care providers. Int J Gynaecol Obstet 103(2):111–115 CrossRefPubMed
7.
Zurück zum Zitat Danhauer SC, Tooze JA, Farmer DF, Campbell CR, McQuellon RP, Barrett R et al (2008) Restorative yoga for women with ovarian or breast cancer: findings from a pilot study. J Soc Integr Oncol 6(2):47–58 PubMed Danhauer SC, Tooze JA, Farmer DF, Campbell CR, McQuellon RP, Barrett R et al (2008) Restorative yoga for women with ovarian or breast cancer: findings from a pilot study. J Soc Integr Oncol 6(2):47–58 PubMed
8.
Zurück zum Zitat León-Pizarro C, Gich I, Barthe E, Rovirosa A, Farrús B, Casas F et al (2007) A randomized trial of the effect of training in relaxation and guided imagery techniques in improving psychological and quality-of-life indices for gynecologic and breast brachytherapy patients. Psycho-Oncology 16(11):971–979 CrossRefPubMed León-Pizarro C, Gich I, Barthe E, Rovirosa A, Farrús B, Casas F et al (2007) A randomized trial of the effect of training in relaxation and guided imagery techniques in improving psychological and quality-of-life indices for gynecologic and breast brachytherapy patients. Psycho-Oncology 16(11):971–979 CrossRefPubMed
9.
Zurück zum Zitat Gross AH, Cromwell J, Fonteyn M, Matulonis UA, Hayman LL (2012) Hopelessness and complementary therapy use in patients with ovarian cancer. Cancer Nurs 36(4):256–264 Gross AH, Cromwell J, Fonteyn M, Matulonis UA, Hayman LL (2012) Hopelessness and complementary therapy use in patients with ovarian cancer. Cancer Nurs 36(4):256–264
10.
Zurück zum Zitat Ahn WS, Kim DJ, Chae GT, Lee JM, Bae SM, Sin JI et al (2004) Natural killer cell activity and quality of life were improved by consumption of a mushroom extract, Agaricus blazei Murill Kyowa, in gynecological cancer patients undergoing chemotherapy. Int J Gynecol Cancer 14(4):589–594 CrossRefPubMed Ahn WS, Kim DJ, Chae GT, Lee JM, Bae SM, Sin JI et al (2004) Natural killer cell activity and quality of life were improved by consumption of a mushroom extract, Agaricus blazei Murill Kyowa, in gynecological cancer patients undergoing chemotherapy. Int J Gynecol Cancer 14(4):589–594 CrossRefPubMed
11.
Zurück zum Zitat Sieja K, Talerczyk M (2004) Selenium as an element in the treatment of ovarian cancer in women receiving chemotherapy. Gynecol Oncol 93(2):320–327 CrossRefPubMed Sieja K, Talerczyk M (2004) Selenium as an element in the treatment of ovarian cancer in women receiving chemotherapy. Gynecol Oncol 93(2):320–327 CrossRefPubMed
12.
Zurück zum Zitat You Q, Yu H, Wu D, Zhang Y, Zheng J, Peng C (2009) Vitamin B6 points PC6 injection during acupuncture can relieve nausea and vomiting in patients with ovarian cancer. Int J Gynecol Cancer 19(4):567–571 CrossRefPubMed You Q, Yu H, Wu D, Zhang Y, Zheng J, Peng C (2009) Vitamin B6 points PC6 injection during acupuncture can relieve nausea and vomiting in patients with ovarian cancer. Int J Gynecol Cancer 19(4):567–571 CrossRefPubMed
13.
Zurück zum Zitat Lu W, Matulonis UA, Doherty-Gilman A, Lee H, Dean-Clower E, Rosulek A, Gibson C et al (2009) Acupuncture for chemotherapy-induced neutropenia in patients with gynecologic malignancies: a pilot randomized, sham-controlled clinical trial. J Altern Complement Med 15(7):745–753 PubMedCentralCrossRefPubMed Lu W, Matulonis UA, Doherty-Gilman A, Lee H, Dean-Clower E, Rosulek A, Gibson C et al (2009) Acupuncture for chemotherapy-induced neutropenia in patients with gynecologic malignancies: a pilot randomized, sham-controlled clinical trial. J Altern Complement Med 15(7):745–753 PubMedCentralCrossRefPubMed
14.
Zurück zum Zitat Delia P, Sansotta G, Donato V, Frosina P, Messina G, De Renzis C et al (2007) Use of probiotics for prevention of radiation-induced diarrhea. World J Gastroenterol 13(6):912–915 PubMedCentralCrossRefPubMed Delia P, Sansotta G, Donato V, Frosina P, Messina G, De Renzis C et al (2007) Use of probiotics for prevention of radiation-induced diarrhea. World J Gastroenterol 13(6):912–915 PubMedCentralCrossRefPubMed
15.
Zurück zum Zitat Etheridge AS, Kroll DJ, Mathews JM (2009) Inhibition of paclitaxel metabolism in vitro in human hepatocytes by Ginkgo biloba preparations. J Diet Suppl 6(2):104–110 CrossRefPubMed Etheridge AS, Kroll DJ, Mathews JM (2009) Inhibition of paclitaxel metabolism in vitro in human hepatocytes by Ginkgo biloba preparations. J Diet Suppl 6(2):104–110 CrossRefPubMed
16.
Zurück zum Zitat Abouzeid AH, Patel NR, Torchilin VP (2014) Polyethylene glycol-phosphatidylethanolamine (PEG-PE)/vitamin E micelles for co-delivery of paclitaxel and curcumin to overcome multi-drug resistance in ovarian cancer. Int J Pharm 464(1–2):178–184 PubMedCentralCrossRefPubMed Abouzeid AH, Patel NR, Torchilin VP (2014) Polyethylene glycol-phosphatidylethanolamine (PEG-PE)/vitamin E micelles for co-delivery of paclitaxel and curcumin to overcome multi-drug resistance in ovarian cancer. Int J Pharm 464(1–2):178–184 PubMedCentralCrossRefPubMed
17.
Zurück zum Zitat Ben-Arye E, Schiff E, Shapira C, Frenkel M, Shalom T, Steiner M (2012) Modeling an integrative oncology program within a community-centered oncology service in Israel. Patient Educ Couns 89(3):423–429 CrossRefPubMed Ben-Arye E, Schiff E, Shapira C, Frenkel M, Shalom T, Steiner M (2012) Modeling an integrative oncology program within a community-centered oncology service in Israel. Patient Educ Couns 89(3):423–429 CrossRefPubMed
18.
Zurück zum Zitat Ben-Arye E, Schiff E, Steiner M, Keshet Y, Lavie O (2012) Attitudes of patients with gynecological and breast cancer toward integration of complementary medicine in cancer care. Int J Gynecol Cancer 22(1):146–153 CrossRefPubMed Ben-Arye E, Schiff E, Steiner M, Keshet Y, Lavie O (2012) Attitudes of patients with gynecological and breast cancer toward integration of complementary medicine in cancer care. Int J Gynecol Cancer 22(1):146–153 CrossRefPubMed
19.
20.
Zurück zum Zitat Paterson C, Thomas K, Manasse A, Cooke H, Peace G (2007) Measure Yourself Concerns and Wellbeing (MYCAW): an individualized questionnaire for evaluating outcome in cancer support care that includes complementary therapies. Complement Ther Med 15(1):38–45 CrossRefPubMed Paterson C, Thomas K, Manasse A, Cooke H, Peace G (2007) Measure Yourself Concerns and Wellbeing (MYCAW): an individualized questionnaire for evaluating outcome in cancer support care that includes complementary therapies. Complement Ther Med 15(1):38–45 CrossRefPubMed
21.
Zurück zum Zitat Ben-Arie E, Kruger D, Samuels N, Keinan-Boker L, Shalom T, Schiff E (2014) Assessing patient adherence to a complementary medicine treatment regimen in an integrative supportive care setting. Support Care Cancer 22(3):627–644 CrossRef Ben-Arie E, Kruger D, Samuels N, Keinan-Boker L, Shalom T, Schiff E (2014) Assessing patient adherence to a complementary medicine treatment regimen in an integrative supportive care setting. Support Care Cancer 22(3):627–644 CrossRef
22.
Zurück zum Zitat von Gruenigen VE, Frasure HE, Jenison EL, Hopkins MP, Gil KM (2006) Longitudinal assessment of quality of life and lifestyle in newly diagnosed ovarian cancer patients: the roles of surgery and chemotherapy. Gynecol Oncol 103(1):120–126 CrossRef von Gruenigen VE, Frasure HE, Jenison EL, Hopkins MP, Gil KM (2006) Longitudinal assessment of quality of life and lifestyle in newly diagnosed ovarian cancer patients: the roles of surgery and chemotherapy. Gynecol Oncol 103(1):120–126 CrossRef
23.
Zurück zum Zitat Andersen MR, Sweet E, Lowe KA, Standish LJ, Drescher CW, Goff BA (2012) Involvement in decision-making about treatment and ovarian cancer survivor quality of life. Gynecol Oncol 124(3):465–470 CrossRefPubMed Andersen MR, Sweet E, Lowe KA, Standish LJ, Drescher CW, Goff BA (2012) Involvement in decision-making about treatment and ovarian cancer survivor quality of life. Gynecol Oncol 124(3):465–470 CrossRefPubMed
24.
Zurück zum Zitat King MT, Stockler MR, Butow P, O’Connell R, Voysey M, Oza AM et al (2014) Development of the measure of ovarian symptoms and treatment concerns: aiming for optimal measurement of patient-reported symptom benefit with chemotherapy for symptomatic ovarian cancer. Int J Gynecol Cancer 24(5):865–867 CrossRefPubMed King MT, Stockler MR, Butow P, O’Connell R, Voysey M, Oza AM et al (2014) Development of the measure of ovarian symptoms and treatment concerns: aiming for optimal measurement of patient-reported symptom benefit with chemotherapy for symptomatic ovarian cancer. Int J Gynecol Cancer 24(5):865–867 CrossRefPubMed
Metadaten
Titel
Quality-of-life outcomes in patients with gynecologic cancer referred to integrative oncology treatment during chemotherapy
verfasst von
Eran Ben-Arye
Noah Samuels
Elad Schiff
Orit Gressel Raz
Ilanit Shalom Sharabi
Ofer Lavie
Publikationsdatum
01.12.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 12/2015
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-015-2690-0

Weitere Artikel der Ausgabe 12/2015

Supportive Care in Cancer 12/2015 Zur Ausgabe

Neu im Fachgebiet Onkologie

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.